An international placebo-controlled randomized multicenter trial of nimorazole with accelerated chemo-radiotherapy for locally advanced HPV-negative squamous cell carcinoma of the head and neck (HNSCC).

Date publication

octobre 2025

Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr VULQUIN Noémie

Tous les auteurs :
Grégoire V, Tao Y, Kaanders J, Machiels JP, Vulquin N, Nuyts S, Doornaert P, Alsner J, Overgaard J

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41138857

Résumé

To evaluate the benefit of the hypoxic radiosensitizer nimorazole (NIM) with accelerated concomitant chemo-radiotherapy in patients with advanced squamous cell carcinoma of the head and neck (HNSCC).

Mots clés

Cisplatin, Concomitant chemo-radiotherapy, Hypoxia, Locally advanced head and neck squamous cell carcinoma, Nimorazole

Référence

Radiother Oncol. 2025 10 23;:111227